BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
35.11
-1.29 (-3.54%)
At close: Mar 28, 2025, 4:00 PM
34.91
-0.20 (-0.57%)
After-hours: Mar 28, 2025, 7:16 PM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 52.9, with a low estimate of 45 and a high estimate of 95. The average target predicts an increase of 50.67% from the current stock price of 35.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $44 → $50 | Buy | Maintains | $44 → $50 | +42.41% | Mar 24, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $45 → $49 | Strong Buy | Maintains | $45 → $49 | +39.56% | Feb 21, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $95 | Buy | Reiterates | $95 | +170.58% | Feb 21, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $49 → $52 | Buy | Maintains | $49 → $52 | +48.11% | Feb 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $49 | Strong Buy | Reiterates | $49 | +39.56% | Feb 13, 2025 |
Financial Forecast
Revenue This Year
235.90M
from 221.90M
Increased by 6.31%
Revenue Next Year
545.33M
from 235.90M
Increased by 131.17%
EPS This Year
-3.73
from -2.88
EPS Next Year
-2.80
from -3.73
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 324.5M | 801.3M | 1.4B | ||
| Avg | 235.9M | 545.3M | 1.0B | ||
| Low | 138.2M | 387.1M | 752.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 46.2% | 239.7% | 162.2% | ||
| Avg | 6.3% | 131.2% | 88.3% | ||
| Low | -37.7% | 64.1% | 38.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.82 | -1.05 | -1.70 | ||
| Avg | -3.73 | -2.80 | -1.97 | ||
| Low | -4.42 | -3.75 | -2.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.